It is well known that prostate cancer is relatively radio-resistant compared to other kinds of cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, dose lewvel, radiation, risk, salvage | Leave a comment »
Whether whole pelvic radiation therapy (WPRT) is beneficial for men newly diagnosed with Gleason grade 9/10 (Grade Group 5) is controversial. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: 10, 9, Gleason, pelvic, primary, radiation, score, whole | 1 Comment »
Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: body, intermediate risk, low risk, radiation, SBRT, stereotactic | 1 Comment »
While excellent outcomes of stereotactic body radiation therapy (SBRT) have been reported since it was first used to treat prostate cancer in 2003, the delivered doses have ranged from 35 Gy in five treatments to 40 Gy in five treatments. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: body, dose, optimal, radiation, SBRT, stereotactic | 6 Comments »
A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CT, free, gallium-68, PET, PSMA-11, radiation, salvage, scan, SRT, therapy | 4 Comments »
Stereotactic body radiation therapy or SBRT (sometimes referred to as SABR or SHARP or CyberKnife) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: body, intermediate, low, radiation, risk, SBRT, sterotactic | 10 Comments »
We didn’t expect to see data from the SPPORT trial for another 2 years, but the research team hit their recruitment goal early and have already been able to provide 5-year results. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, clinical, post-prostatectomy, radiation, recurrence, salvage, SPPORT | 14 Comments »
